Related Experiment Video
Updated: Sep 11, 2025
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
HLA association with azathioprine-induced pancreatitis in patients with inflammatory bowel disease: A case series
Sidharth Harindranath1, Rajeshwari B2, Suchita J2
1Division of Gastroenterology, P. D. Hinduja Hospital and Medical Research Center, Veer Savarkar Marg, Mahim, Mumbai, 400 016, India.
Background:
Azathioprine (AZA)-induced pancreatitis is a significant adverse event affecting patients with inflammatory bowel disease (IBD). A genetic association with HLA-DRB1*07 and HLA-DQA1*02 alleles polymorphisms has been reported, but its prevalence and impact on Asian patients with IBD remain unclear.
Methods:
A retrospective review of a prospectively maintained database of patients with IBD was done from January 2005 till December 2024. Patients who developed pancreatitis were tested for HLA association with HLA class II-DRB1*07 and HLA-DQA1*02 alleles. Duration of AZA, dose of AZA and other risk factors such as smoking, alcohol intake, steroid administration, previous history of pancreatitis and any other risk factors for pancreatitis were noted. These patients were compared with a matched control group of non-IBD patients undergoing human leukocyte antigen (HLA) typing for other indications.
Results:
Of 1751 patients with IBD, 441 (25.1%) were exposed to AZA 12/441 (2.7%) developed azathioprine-induced pancreatitis. Patients with pancreatitis had a significantly higher prevalence of the HLA-DRB1*07 and HLA-DQA1*02 haplotype compared to controls (8/12; 66.6% vs. 1877/7361; 25.4% p = 0.001089). The onset of pancreatitis occurred within a median of 15 days of initiation of AZA, with all cases being mild in severity. Rechallenge confirmed causality in one patient.
Conclusion:
Azathioprine-induced pancreatitis occurred in 2.7% patients. The class-II HLA-DRB1*07 and HLA-DQA1*02 is an important marker for AZA-induced pancreatitis risk. Rechallenge should be avoided in patients with this HLA antigen. More data is required for pre-emptive HLA testing prior to initiation of azathioprine.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...